✓ verbatim from the press
Healthcare workers in Pernambuco vaccinated against dengue with the Butantan vaccine in the last 21 days should undergo monitoring at health units for possible adverse reactions. The guidance was issued by the Pernambuco State Health Department (SES-PE) on Monday (9th), after the Ministry of Health temporarily suspended vaccination of this population nationwide. ✓
Press quotes (1)
"A Secretaria Estadual de Saúde de Pernambuco (SES-PE) orientou que profissionais de saúde que se vacinaram contra a dengue, nos últimos 21 dias, com o imunizante produzido pelo Instituto Butantan, realizem acompanhamento em unidades de saúde para monitoramento de possíveis reações adversas."
The measure affects Primary Health Care workers aged 15 to 59 who were participating in the immunization strategy started in February. In Pernambuco, 11,711 doses have already been administered and recorded in the National Health Data Network (RNDS). SES-PE also instructed municipalities to remove remaining doses from units and store them in municipal cold chains pending new guidance from the Ministry of Health. ✓
Press quotes (1)
"A medida afeta trabalhadores da Atenção Primária à Saúde com idade entre 15 e 59 anos que participavam da estratégia de imunização iniciada em fevereiro deste ano. Em Pernambuco, 11.711 doses já foram aplicadas e registradas na Rede Nacional de Dados em Saúde (RNDS)."
Vaccinated professionals should watch for symptoms such as fever, intense abdominal pain, persistent vomiting, bleeding, dizziness, excessive drowsiness, signs of dehydration or general deterioration for three weeks after application. If symptoms occur, the guidance is to seek medical attention immediately. Pernambuco's Immunization Superintendent, Magda Costa, emphasized that cases will be monitored by municipal surveillance teams. ✓
Press quotes (1)
"os profissionais vacinados recentemente devem observar seu estado de saúde durante três semanas após a aplicação da dose. Em caso de sintomas como febre, dor abdominal intensa, vômitos persistentes, sangramentos, tontura, sonolência excessiva, sinais de desidratação ou piora do estado geral, a orientação é procurar atendimento médico imediatamente."
The national suspension was adopted after recording 3,703 notifications of unexpected events with dengue-like symptoms between January and May — 0.7% of all immunized people. Of this total, 42 cases showed alarm signs and three were classified as severe, including two deaths under investigation. Vaccination of children and adolescents aged 10 to 14 was not affected, as it uses a vaccine from another manufacturer. ✓
Press quotes (1)
"A suspensão temporária da vacinação foi adotada pelo Ministério da Saúde após o registro, em nível nacional, de 3.703 notificações de eventos inesperados com sintomas semelhantes aos da dengue entre janeiro e maio deste ano. O número representa 0,7% do total de pessoas imunizadas."
The national suspension was based on 3,703 adverse event notifications (0.7% of vaccinated individuals), with 42 cases showing alarm signs and two deaths under investigation
Covered by only some sources, or where the accounts diverge.
Covered by only some sources (2)
Minas Gerais administered over 82,000 doses of Butantan-DV vaccine, with three suspected cases in Nova Lima that were later ruled out
The suspension demonstrates proper functioning of pharmacovigilance systems, being a standard preventive measure
-
What is the specific legal basis that authorizes SES-PE to issue health monitoring guidelines?
Why it's still unknown: No source mentions the normative basis (state law, ordinance, or constitutional competence) that grounds the state health department's guidance.
-
What is the specific clinical protocol for monitoring — duration, frequency of consultations, required laboratory tests?
Why it's still unknown: The guidance mentions 'monitoring at health units' but does not specify concrete procedures beyond symptom observation by the professionals themselves.
-
Are there specific clinical data on the Butantan-DV vaccine that justify differentiated monitoring compared to other vaccines?
Why it's still unknown: Sources report the suspension and recorded adverse events, but do not present the efficacy and safety profile from clinical trials that would contextualize the decision.
-
What is the official position of the Butantan Institute regarding the monitoring recommendation and suspension?
Why it's still unknown: No source presents a statement or position from the Butantan Institute regarding the measures adopted by health authorities.